Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Lymphoproliferative disorder
ADR ID BADD_A05831
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.21      Haematopoietic neoplasms (excl leukaemias and lymphomas)
16.21.02      Lymphoproliferative disorders NEC (excl leukaemias and lymphomas)
16.21.02.001      Lymphoproliferative disorder
01      Blood and lymphatic system disorders
01.13      Haematopoietic neoplasms (excl leukaemias and lymphomas)
01.13.02      Lymphoproliferative disorders NEC (excl leukaemias and lymphomas)
01.13.02.001      Lymphoproliferative disorder
Description Disorders characterized by proliferation of lymphoid tissue, general or unspecified. [MeSH]
MedDRA Code 10061232
MeSH ID D008232; D007160; D008232
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Lymphoproliferative disorder NOS | Other immunoproliferative neoplasms | Other immunoproliferative neoplasms without mention of remission | Lymphoproliferative disorder | Immunoproliferative disorder | KSHV/HHV8-positive germinotropic lymphoproliferative disorder | Lymphoproliferative Disorders | Disorder, Lymphoproliferative | Disorders, Lymphoproliferative | Lymphoproliferative Disorder | X-Linked Lymphoproliferative Disorder | Disorder, X-Linked Lymphoproliferative | Disorders, X-Linked Lymphoproliferative | Lymphoproliferative Disorder, X-Linked | Lymphoproliferative Disorders, X-Linked | X Linked Lymphoproliferative Disorder | X-Linked Lymphoproliferative Disorders | Epstein-Barr Virus Infection, Familial Fatal | Epstein Barr Virus Infection, Familial Fatal | Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males | Epstein Barr Virus Induced Lymphoproliferative Disease In Males | Familial Fatal Epstein-Barr Infection | Familial Fatal Epstein Barr Infection | Immunodeficiency 5 | Immunodeficiency 5s | Duncan's Syndrome | Lymphoproliferative Disease, X-Linked | Disease, X-Linked Lymphoproliferative | Diseases, X-Linked Lymphoproliferative | Lymphoproliferative Disease, X Linked | Lymphoproliferative Diseases, X-Linked | X-Linked Lymphoproliferative Diseases | Lymphoproliferative Syndrome, X-Linked, 1 | Purtilo Syndrome | Purtilo Syndromes | Syndrome, Purtilo | Syndromes, Purtilo | X-Linked Lymphoproliferative Disease | X Linked Lymphoproliferative Disease | X-Linked Lymphoproliferative Syndrome | Lymphoproliferative Syndrome, X-Linked | Lymphoproliferative Syndromes, X-Linked | Syndrome, X-Linked Lymphoproliferative | Syndromes, X-Linked Lymphoproliferative | X Linked Lymphoproliferative Syndrome | X-Linked Lymphoproliferative Syndromes | Duncan Disease | Disease, Duncan | Immunodeficiency, X-Linked Progressive Combined Variable | Immunodeficiency, X Linked Progressive Combined Variable
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00064Alemtuzumab--
BADD_D00195Azathioprine0.000313%
BADD_D00285Bosentan0.000120%
BADD_D00551Cyclosporine0.000111%
BADD_D00858Everolimus--
BADD_D00871Felbamate--
BADD_D00899Fingolimod hydrochloride--
BADD_D00914Fludarabine--
BADD_D00915Fludarabine phosphate--
BADD_D01136Imatinib0.000224%
BADD_D01418Methotrexate0.008983%
BADD_D01419Methotrexate sodium--
BADD_D01507Mycophenolate mofetil--
BADD_D01508Mycophenolic acid--
BADD_D01831Prednisolone0.000140%
BADD_D01834Prednisone0.000018%
BADD_D01858Propagermanium--
BADD_D02028Sirolimus0.000134%
BADD_D02093Sulfasalazine0.000455%
BADD_D02105Tacrolimus0.001931%
BADD_D02236Tofacitinib0.001326%
BADD_D02331Valsartan0.000079%
BADD_D02464Fingolimod0.000362%
The 1th Page    1    Total 1 Pages